124 related articles for article (PubMed ID: 33163363)
1. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotype.
Hopkin RJ; Feldt-Rasmussen U; Germain DP; Jovanovic A; Martins AM; Nicholls K; Ortiz A; Politei J; Ponce E; Varas C; Weidemann F; Yang M; Wilcox WR
Mol Genet Metab Rep; 2020 Dec; 25():100670. PubMed ID: 33163363
[TBL] [Abstract][Full Text] [Related]
2. Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.
Goker-Alpan O; Gambello MJ; Maegawa GH; Nedd KJ; Gruskin DJ; Blankstein L; Weinreb NJ
JIMD Rep; 2016; 25():95-106. PubMed ID: 26303609
[TBL] [Abstract][Full Text] [Related]
3. The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.
Martins AM; Cabrera G; Molt F; Suárez-Obando F; Valdés RA; Varas C; Yang M; Politei JM
JIMD Rep; 2019 Sep; 49(1):107-117. PubMed ID: 31497488
[TBL] [Abstract][Full Text] [Related]
4. Fabry App: the value of a portable technology in recording day-to-day patient monitored information in patients with Fabry disease.
D'Amore S; Mckie M; Fahey A; Bleloch D; Grillo G; Hughes M; Ramaswami U
Orphanet J Rare Dis; 2024 Jan; 19(1):13. PubMed ID: 38212814
[TBL] [Abstract][Full Text] [Related]
5. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
6. Correction: Assessment of plasma lyso-Gb
Bichet DG; Aerts JM; Auray-Blais C; Maruyama H; Mehta AB; Skuban N; Krusinska E; Schiffmann R
Genet Med; 2021 Jan; 23(1):238. PubMed ID: 33219325
[No Abstract] [Full Text] [Related]
7. Histogram features of Fabry disease with pseudonormalization in native T1 mapping.
Oda S; Kidoh M; Morita K; Takashio S; Tsujita K
Eur Heart J Cardiovasc Imaging; 2021 Apr; 22(5):e23. PubMed ID: 33179729
[No Abstract] [Full Text] [Related]
8. [Fabry disease: A review].
Michaud M; Mauhin W; Belmatoug N; Bedreddine N; Garnotel R; Catros F; Lidove O; Gaches F
Rev Med Interne; 2021 Feb; 42(2):110-119. PubMed ID: 33172708
[TBL] [Abstract][Full Text] [Related]
9. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the reasons for the microvascular changes in patients with Fabry disease using optic coherence tomography angiography.
Dogan C; Gonen B; Dincer MT; Mergen B; Kiykim E; Bakir A; Trabulus S; Yetik H; Seyahi N
Eur J Ophthalmol; 2021 Nov; 31(6):3231-3237. PubMed ID: 33225739
[TBL] [Abstract][Full Text] [Related]
11. Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy.
Trimarchi H; Ortiz A; Sánchez-Niño MD
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33203029
[TBL] [Abstract][Full Text] [Related]
12. Scoring system to facilitate diagnosis of Gaucher disease.
Mehta A; Rivero-Arias O; Abdelwahab M; Campbell S; McMillan A; Rolfe MJ; Bright JR; Kuter DJ
Intern Med J; 2020 Dec; 50(12):1538-1546. PubMed ID: 33174353
[TBL] [Abstract][Full Text] [Related]
13. Basal Segmental Longitudinal Strain: A Marker of Subclinical Myocardial Involvement in Anderson-Fabry Disease.
Zada M; Lo Q; Boyd AC; Bradley S; Devine K; Denaro CP; Sadick N; Richards DAB; Tchan MC; Thomas L
J Am Soc Echocardiogr; 2021 Apr; 34(4):405-413.e2. PubMed ID: 33242609
[TBL] [Abstract][Full Text] [Related]
14. Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy.
Graziani F; Lillo R; Panaioli E; Spagnoletti G; Pieroni M; Ferrazzi P; Camporeale A; Verrecchia E; Sicignano LL; Manna R; Crea F
ESC Heart Fail; 2021 Feb; 8(1):725-728. PubMed ID: 33211404
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease pain: patient and preclinical parallels.
Burand AJ; Stucky CL
Pain; 2021 May; 162(5):1305-1321. PubMed ID: 33259456
[TBL] [Abstract][Full Text] [Related]
16. Corneal densitometry: a potential indicator for early diagnosis of Fabry disease.
Li S; Siggel R; Guo Y; Loreck N; Rokohl AC; Kurschat C; Heindl LM
Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):941-948. PubMed ID: 33258999
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.
Reisin RC; Rozenfeld P; Bonardo P
Med Hypotheses; 2020 Nov; 144():110282. PubMed ID: 33254586
[TBL] [Abstract][Full Text] [Related]
18. New treatment for myocardial diseases.
Onoue K; Saito Y
J Cardiol; 2021 Jun; 77(6):620-625. PubMed ID: 33250269
[TBL] [Abstract][Full Text] [Related]
19. EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review.
Poffenberger CN; Inati S; Tayebi N; Stubblefield BK; Ryan E; Schiffmann R; Sidransky E; Lopez G
Mol Genet Metab; 2020 Nov; 131(3):358-363. PubMed ID: 33183916
[TBL] [Abstract][Full Text] [Related]
20. Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy.
Dutra-Clarke M; Tapia D; Curtin E; Rünger D; Lee GK; Lakatos A; Alandy-Dy Z; Freedkin L; Hall K; Ercelen N; Alandy-Dy J; Knight M; Pahl M; Lombardo D; Kimonis V
Mol Genet Metab Rep; 2021 Mar; 26():100700. PubMed ID: 33437642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
